Bank of America Merrill Lynch Reiterates Buy Rating, $25 PT on Pfizer
In a report published Monday, Bank of America Merrill Lynch reiterated its Buy rating and $25.00 price target on Pfizer (NYSE: PFE).
BofA Merrill Lynch noted, “Given the upcoming FDA PDUFA data for PFE's novel treatment for RA (tofacitinib), the recent Complete Response letter for Eliquis and the upcoming data for bapineuzumab, we expect all three of these drugs to be points of focus on the call. We will also be paying attention to updated financial details (proceeds to PFE) on the sale of the nutrition business as well as any commentary on the sale/spin of the Animal Health business.”
Pfizer closed on Friday at $23.70.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.